Novo Nordisk A/ S stock (DK0060534915): obesity-drug leader lifts outlook after strong GLP?1 demand

Novo Nordisk A/S has raised its 2026 profit outlook on surging demand for its obesity and diabetes drugs Wegovy and Ozempic, while investors weigh capacity expansion, US pricing risks and intensifying competition in GLP?1 therapies.

Novo Nordisk A/S has updated its financial guidance for 2026 and reported continued strong demand for its GLP?1 diabetes and obesity treatments, including Ozempic and Wegovy, prompting investors to reassess growth expectations for the Danish drug maker’s stock, according to a company announcement and recent market data from early May 2026, as reported by Novo Nordisk investor information as of 05/2026 and coverage by Reuters as of 05/2026.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novo Nordisk
• Sector/industry: Pharmaceuticals, diabetes and obesity care
• Headquarters/country: Bagsværd, Denmark
• Core markets: Global, with major exposure to the US and Europe
• Key revenue drivers: GLP?1 therapies for diabetes and obesity (e.g., Ozempic, Wegovy), insulin portfolio, rare disease treatments
• Home exchange/listing venue: Nasdaq Copenhagen (ticker: NOVO?B); US investors often access the stock via ADRs on the New York Stock Exchange
• Trading currency: Danish krone (DKK) in Copenhagen

Novo Nordisk A/S: core business model

Novo Nordisk focuses on chronic disease treatments, with a particular emphasis on diabetes and obesity, conditions that affect hundreds of millions of people worldwide and represent long?term therapy markets. The company’s strategy is centered on developing innovative biologic drugs that can command premium pricing and create strong patient loyalty, especially in areas where treatment options were historically limited, according to Novo Nordisk corporate information as of 2025.

The business model relies on a mix of patented injectable therapies and, increasingly, oral formulations that leverage Novo Nordisk’s GLP?1 technology platform. These medicines are often prescribed for long durations, which contributes to recurring revenue streams and relatively high visibility on future cash flows, as highlighted in the company’s annual reporting for 2024 published in early 2025 by Novo Nordisk annual report 2024 as of 02/2025.

Over the past years, management has expanded beyond traditional insulin into broader metabolic and cardiovascular risk reduction. This includes trials assessing whether GLP?1 therapies can lower the risk of heart events or kidney complications in people with obesity or type 2 diabetes, which may support future label expansions and reimbursement decisions, subject to regulatory approval, according to clinical program updates from Novo Nordisk news materials as of 2025.

Novo Nordisk also maintains a portfolio in rare diseases, such as hemophilia and growth disorders, though these segments are smaller compared to the scale of its diabetes and obesity franchise. For the overall business, the company points to demographic trends, rising obesity rates, and healthcare system focus on prevention as structural drivers that support long?term demand, based on comments in recent investor presentations summarized by Reuters as of 11/2025.

Main revenue and product drivers for Novo Nordisk A/S

The GLP?1 drug class is now the main revenue engine for Novo Nordisk. Ozempic, originally launched for type 2 diabetes, has become a blockbuster medicine, with double?digit sales growth in 2024 driven by strong uptake in the US market and expanding demand in Europe and other regions, according to the company’s 2024 results release published in early 2025 by Novo Nordisk results material as of 02/2025.

Wegovy, Novo Nordisk’s obesity drug based on the same active substance as Ozempic but dosed for weight?management, has been a key driver of the recent upgrade in the company’s medium?term outlook. The drug has experienced periods of constrained supply because demand outpaced production, particularly in the US, where it has been widely covered in mainstream media and social networks, according to coverage by Reuters as of 09/2024.

To address those bottlenecks, Novo Nordisk has been investing heavily in manufacturing capacity, including expansions in Denmark and the US and acquisitions of additional production sites. One notable step was its agreement to acquire certain manufacturing facilities from Catalent, a contract development and manufacturing organization, with the goal to secure more fill?and?finish capacity for GLP?1 products, as outlined in a transaction announcement covered by Reuters as of 02/05/2024.

Beyond Ozempic and Wegovy, the company markets Rybelsus, an oral semaglutide formulation, which allows patients to take GLP?1 therapy in pill form rather than via injection. Oral treatments may broaden the addressable market, particularly among patients who are reluctant to start injections, and thus represent a strategic extension of Novo Nordisk’s GLP?1 franchise, according to product information summarized in Novo Nordisk product data as of 2025.

Insulin remains a substantial, though relatively slower?growing, revenue contributor. The portfolio includes modern and next?generation insulin products designed to offer more stable blood sugar control and flexible dosing. However, in developed markets like the US, insulin pricing has faced political scrutiny and policy initiatives to cap out?of?pocket costs, limiting price growth and encouraging manufacturers to provide discounts or savings programs, as detailed in US policy coverage by Reuters as of 03/2023.

Within rare diseases, Novo Nordisk generates revenue from hemophilia treatments and growth hormone therapies. While these products address smaller patient populations, they typically carry high prices and can enjoy relatively long patent protection, providing an additional layer of diversification. Still, from an equity perspective, the long?term narrative around the stock currently revolves primarily around GLP?1 demand, obesity care penetration, and potential new indications for related medicines, as highlighted by multiple sell?side reports summarized in financial media pieces such as Reuters as of 08/2025.

Industry trends and competitive position

The broader pharmaceutical industry has increasingly focused on obesity and metabolic diseases as growth areas. Analysts have estimated that the global obesity drug market could reach tens of billions of dollars in annual sales over the coming decade, with GLP?1 and related mechanisms at the center of this expansion, according to market forecasts cited in a sector overview by Reuters as of 10/2024.

Novo Nordisk’s main competitor in this space is Eli Lilly, which markets the diabetes and obesity drugs Mounjaro and Zepbound based on the tirzepatide molecule. Both companies have reported strong demand and have faced similar capacity challenges, especially in the US. The competitive dynamic has pushed each company to accelerate manufacturing investments and broaden clinical development programs, as described in earnings coverage by Reuters as of 2025.

From a competitive standpoint, Novo Nordisk benefits from a long track record in diabetes care, deep relationships with endocrinologists, and a substantial global distribution network. However, payers and regulators are increasingly scrutinizing the cost of obesity therapies, particularly when prescribed for large populations over extended periods. Health technology assessments and real?world outcomes data could therefore play a key role in determining how broadly these medicines are reimbursed, which in turn will influence adoption rates and long?term revenue potential, as discussed in European reimbursement coverage by Reuters as of 12/2024.

Why Novo Nordisk A/S matters for US investors

For US investors, Novo Nordisk represents a non?US company with significant exposure to the US healthcare system, given that the US is the largest single market for its diabetes and obesity drugs. The company’s performance is therefore influenced by US prescription trends, reimbursement decisions, and potential legislative initiatives affecting drug pricing or insurance coverage, as highlighted in the company’s risk disclosures in the 2024 annual report published by Novo Nordisk annual report 2024 as of 02/2025.

Novo Nordisk’s shares trade in Copenhagen, but many US investors access the stock via American depositary receipts listed on the New York Stock Exchange, which provide dollar?denominated exposure. This adds an additional layer of currency considerations because the company reports in Danish krone, meaning that exchange rate movements between DKK and USD can influence reported results when converted to dollars and impact US?based portfolio valuations, as noted in cross?listing information from NYSE data as of 2025.

US investors also often compare Novo Nordisk directly with Eli Lilly and, to a lesser extent, other pharmaceutical and biotech companies working on metabolic disease treatments. In that context, valuation metrics such as price?to?earnings ratios, revenue growth rates, and margin profiles are frequently discussed in financial media, but individual investors may wish to consider how much of the GLP?1 growth story is already reflected in the share price versus the risks of competitive pressure, pricing constraints, or safety findings emerging from longer?term use, as debated in commentary compiled by Reuters as of 01/2025.

Conclusion

Novo Nordisk A/S has become a central player in the global obesity and diabetes treatment landscape, with GLP?1 therapies such as Ozempic, Wegovy, and Rybelsus driving strong revenue and prompting management to lift its longer?term outlook. At the same time, the company faces practical challenges in scaling manufacturing, navigating evolving reimbursement policies, and defending its market share against well?capitalized competitors like Eli Lilly. For US?focused investors, the stock offers exposure to a major global healthcare theme but also embeds regulatory, pricing, and execution risks that could influence future growth and valuation, particularly if the obesity drug market develops differently from current expectations.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.